The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SNTI | -69.85% | N/A | N/A | -99% |
| S&P | +16.49% | +84.25% | +12.99% | +63% |
Senti Biosciences, Inc. is a biotechnology company. It engages in the business of developing next-generation cell and gene therapies engineered with a gene circuit platform technology to fight challenging diseases. The company was founded by Timothy K. Lu, Wilson Wong, and Philip Lee on June 9, 2016 and is headquartered in South San Francisco, CA.
No news articles found for Senti Biosciences.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$904.00K | 38.3% |
| Market Cap | $36.89M | 256.4% |
| Market Cap / Employee | $1.08M | 0.0% |
| Employees | 34 | -29.2% |
| Net Income | -$18,126.00K | 37.2% |
| EBITDA | -$16,044.00K | -19.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $12.24M | 16.8% |
| Accounts Receivable | $147.00K | 98.6% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $24.97M | -17.1% |
| Short Term Debt | $5.15M | 12.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -86.19% | -11.4% |
| Return On Invested Capital | -61.97% | -1.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$9,446.00K | -20.1% |
| Operating Free Cash Flow | -$9,446.00K | -20.1% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.01 | 0.63 | 1.45 | 1.50 | 539.17% |
| Price to Sales | 11.51 | 13.52 | 37.33 | - | |
| Price to Tangible Book Value | 1.01 | 0.63 | 1.45 | 1.50 | 539.17% |
| Enterprise Value to EBITDA | -1.82 | -2.16 | -4.23 | -3.42 | 32.90% |
| Return on Equity | -89.7% | -116.6% | -169.5% | -394.6% | 175.44% |
| Total Debt | $33.64M | $32.45M | $31.31M | $30.12M | -13.22% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
